208 related articles for article (PubMed ID: 36037364)
21. Identification of novel VHL target genes and relationship to hypoxic response pathways.
Maina EN; Morris MR; Zatyka M; Raval RR; Banks RE; Richards FM; Johnson CM; Maher ER
Oncogene; 2005 Jun; 24(28):4549-58. PubMed ID: 15824735
[TBL] [Abstract][Full Text] [Related]
22. BAP1 maintains HIF-dependent interferon beta induction to suppress tumor growth in clear cell renal cell carcinoma.
Langbein LE; El Hajjar R; He S; Sementino E; Zhong Z; Jiang W; Leiby BE; Li L; Uzzo RG; Testa JR; Yang H
Cancer Lett; 2022 Oct; 547():215885. PubMed ID: 35995140
[TBL] [Abstract][Full Text] [Related]
23. Epigenetic regulation of HIF-1α in renal cancer cells involves HIF-1α/2α binding to a reverse hypoxia-response element.
Xu J; Wang B; Xu Y; Sun L; Tian W; Shukla D; Barod R; Grillari J; Grillari-Voglauer R; Maxwell PH; Esteban MA
Oncogene; 2012 Feb; 31(8):1065-72. PubMed ID: 21841824
[TBL] [Abstract][Full Text] [Related]
24. Interplay between pVHL and mTORC1 pathways in clear-cell renal cell carcinoma.
Kucejova B; Peña-Llopis S; Yamasaki T; Sivanand S; Tran TA; Alexander S; Wolff NC; Lotan Y; Xie XJ; Kabbani W; Kapur P; Brugarolas J
Mol Cancer Res; 2011 Sep; 9(9):1255-65. PubMed ID: 21798997
[TBL] [Abstract][Full Text] [Related]
25. Zafirlukast Induces VHL- and HIF-2α-Dependent Oxidative Cell Death in 786-O Clear Cell Renal Carcinoma Cells.
Wolf C; Smith S; van Wijk SJL
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408930
[TBL] [Abstract][Full Text] [Related]
26. Di-Ras2 promotes renal cell carcinoma formation by activating the mitogen-activated protein kinase pathway in the absence of von Hippel-Lindau protein.
Rao H; Li X; Liu M; Liu J; Li X; Xu J; Li L; Gao WQ
Oncogene; 2020 May; 39(19):3853-3866. PubMed ID: 32161311
[TBL] [Abstract][Full Text] [Related]
27. Genome-wide Screening Identifies SFMBT1 as an Oncogenic Driver in Cancer with VHL Loss.
Liu X; Simon JM; Xie H; Hu L; Wang J; Zurlo G; Fan C; Ptacek TS; Herring L; Tan X; Li M; Baldwin AS; Kim WY; Wu T; Kirschner MW; Gong K; Zhang Q
Mol Cell; 2020 Mar; 77(6):1294-1306.e5. PubMed ID: 32023483
[TBL] [Abstract][Full Text] [Related]
28. A Hypoxia-Inducible HIF1-GAL3ST1-Sulfatide Axis Enhances ccRCC Immune Evasion via Increased Tumor Cell-Platelet Binding.
Robinson CM; Poon BPK; Kano Y; Pluthero FG; Kahr WHA; Ohh M
Mol Cancer Res; 2019 Nov; 17(11):2306-2317. PubMed ID: 31427440
[TBL] [Abstract][Full Text] [Related]
29. VHL mutation-mediated SALL4 overexpression promotes tumorigenesis and vascularization of clear cell renal cell carcinoma via Akt/GSK-3β signaling.
Sun J; Tang Q; Gao Y; Zhang W; Zhao Z; Yang F; Hu X; Zhang D; Wang Y; Zhang H; Song B; Zhang B; Wang H
J Exp Clin Cancer Res; 2020 Jun; 39(1):104. PubMed ID: 32513235
[TBL] [Abstract][Full Text] [Related]
30. pVHL/HIF-regulated CD70 expression is associated with infiltration of CD27+ lymphocytes and increased serum levels of soluble CD27 in clear cell renal cell carcinoma.
Ruf M; Mittmann C; Nowicka AM; Hartmann A; Hermanns T; Poyet C; van den Broek M; Sulser T; Moch H; Schraml P
Clin Cancer Res; 2015 Feb; 21(4):889-98. PubMed ID: 25691774
[TBL] [Abstract][Full Text] [Related]
31. Role of the VHL (von Hippel-Lindau) gene in renal cancer: a multifunctional tumour suppressor.
Nyhan MJ; O'Sullivan GC; McKenna SL
Biochem Soc Trans; 2008 Jun; 36(Pt 3):472-8. PubMed ID: 18481984
[TBL] [Abstract][Full Text] [Related]
32. VHL gene mutations and their effects on hypoxia inducible factor HIFα: identification of potential driver and passenger mutations.
Rechsteiner MP; von Teichman A; Nowicka A; Sulser T; Schraml P; Moch H
Cancer Res; 2011 Aug; 71(16):5500-11. PubMed ID: 21715564
[TBL] [Abstract][Full Text] [Related]
33. The SWI/SNF Protein PBRM1 Restrains VHL-Loss-Driven Clear Cell Renal Cell Carcinoma.
Nargund AM; Pham CG; Dong Y; Wang PI; Osmangeyoglu HU; Xie Y; Aras O; Han S; Oyama T; Takeda S; Ray CE; Dong Z; Berge M; Hakimi AA; Monette S; Lekaye CL; Koutcher JA; Leslie CS; Creighton CJ; Weinhold N; Lee W; Tickoo SK; Wang Z; Cheng EH; Hsieh JJ
Cell Rep; 2017 Mar; 18(12):2893-2906. PubMed ID: 28329682
[TBL] [Abstract][Full Text] [Related]
34. Epigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer.
Vanharanta S; Shu W; Brenet F; Hakimi AA; Heguy A; Viale A; Reuter VE; Hsieh JJ; Scandura JM; Massagué J
Nat Med; 2013 Jan; 19(1):50-6. PubMed ID: 23223005
[TBL] [Abstract][Full Text] [Related]
35. VHL-HIF-2α axis-induced SEMA6A upregulation stabilized β-catenin to drive clear cell renal cell carcinoma progression.
Ji J; Xu Y; Xie M; He X; Ren D; Qiu T; Liu W; Chen Z; Shi W; Zhang Z; Wang X; Wang W; Ma J; Qian Q; Jing A; Ma X; Qin J; Ding Y; Geng T; Yang J; Sun Z; Liu W; Liu S; Liu B
Cell Death Dis; 2023 Feb; 14(2):83. PubMed ID: 36739418
[TBL] [Abstract][Full Text] [Related]
36. Deubiquitylase OTUD6B stabilizes the mutated pVHL and suppresses cell migration in clear cell renal cell carcinoma.
Guo K; Wei Y; Wang Z; Zhang X; Zhang X; Liu X; Wu W; Wu Z; Zhang L; Cui CP
Cell Death Dis; 2022 Feb; 13(2):97. PubMed ID: 35110537
[TBL] [Abstract][Full Text] [Related]
37. Rho-associated kinase 1 inhibition is synthetically lethal with von Hippel-Lindau deficiency in clear cell renal cell carcinoma.
Thompson JM; Nguyen QH; Singh M; Pavesic MW; Nesterenko I; Nelson LJ; Liao AC; Razorenova OV
Oncogene; 2017 Feb; 36(8):1080-1089. PubMed ID: 27841867
[TBL] [Abstract][Full Text] [Related]
38. The uremic toxin p-cresyl sulfate induces proliferation and migration of clear cell renal cell carcinoma via microRNA-21/ HIF-1α axis signals.
Wu TK; Wei CW; Pan YR; Hsu RJ; Wu CY; Yu YL
Sci Rep; 2019 Mar; 9(1):3207. PubMed ID: 30824757
[TBL] [Abstract][Full Text] [Related]
39. The up-regulation of NDRG1 by HIF counteracts the cancer-promoting effect of HIF in VHL-deficient clear cell renal cell carcinoma.
Zhang ZY; Zhang SL; Chen HL; Mao YQ; Li ZM; Kong CY; Han B; Zhang J; Chen YH; Xue W; Zhai W; Wang LS
Cell Prolif; 2020 Jul; 53(7):e12853. PubMed ID: 32537867
[TBL] [Abstract][Full Text] [Related]
40.
Yao X; Tan J; Lim KJ; Koh J; Ooi WF; Li Z; Huang D; Xing M; Chan YS; Qu JZ; Tay ST; Wijaya G; Lam YN; Hong JH; Lee-Lim AP; Guan P; Ng MSW; He CZ; Lin JS; Nandi T; Qamra A; Xu C; Myint SS; Davies JOJ; Goh JY; Loh G; Tan BC; Rozen SG; Yu Q; Tan IBH; Cheng CWS; Li S; Chang KTE; Tan PH; Silver DL; Lezhava A; Steger G; Hughes JR; Teh BT; Tan P
Cancer Discov; 2017 Nov; 7(11):1284-1305. PubMed ID: 28893800
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
